TrialLancet (London, England)2019

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Tony S K Mok et al.PubMed ↗Publisher ↗

No numbers read from the abstract.